These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 5019376)

  • 1. [The effect of renal insufficiency on the hypoglycemic action of sulfonylureas. Kinetics of chlorpropamide in a case of nephropathy].
    Pettipierre B; Fabre J
    Schweiz Med Wochenschr; 1972 Apr; 102(16):570-8. PubMed ID: 5019376
    [No Abstract]   [Full Text] [Related]  

  • 2. [Kinetics of chlorpropamide in renal insufficiency. Effect of associated therapeutics].
    Fabre J; Rudhardt M; Petitpierre B; Perrin L
    J Urol Nephrol (Paris); 1971 Dec; 77(12):960-2. PubMed ID: 5151207
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and biotransformation of chlorpropamide in the rat and dog.
    Taylor JA
    Drug Metab Dispos; 1974; 2(3):221-7. PubMed ID: 4152995
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical use of the sulfonylurea drugs.
    Blumenthal SA; Moses AM
    Compr Ther; 1976 Jul; 2(2):53-8. PubMed ID: 954381
    [No Abstract]   [Full Text] [Related]  

  • 5. ["First" and "second" generation sulfonylureas: distinction or difference? (author's transl)].
    Balant L
    Diabete Metab; 1978 Jun; 4(2):135-43. PubMed ID: 98364
    [No Abstract]   [Full Text] [Related]  

  • 6. Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.
    Petitpierre B; Perrin L; Rudhardt M; Herrera A; Fabre J
    Int J Clin Pharmacol; 1972 Jun; 6(2):120-4. PubMed ID: 4638970
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation between serum concentration and hypoglycemic effect of chlorpropamide in man.
    Jankowski A; Wichliński LM; Bokowski W; Romański B
    Pol J Pharmacol Pharm; 1984; 36(5):449-53. PubMed ID: 6533629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of deficient kidney function on behavior of glipizide (hypoglycemic sulfonylurea) and its metabolites].
    Fabre J; Balant L; Zahnd G
    J Urol Nephrol (Paris); 1973; 79(4):380-1. PubMed ID: 4720133
    [No Abstract]   [Full Text] [Related]  

  • 9. [88 severe incidents of hypoglycemia in patients under treatment with sulfonylurea compounds. Results of a survey throughout Switzerland during 1968 and 1969].
    Berger W
    Schweiz Med Wochenschr; 1971 Jul; 101(28):1013-22. PubMed ID: 5141777
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hyponatremia and hypoglycemia after treatment with chlorpropamide. Case histories with review of the literature on 18 cases of chlorpropamide induced hyponatremia].
    Bründler H; Berger W
    Schweiz Med Wochenschr; 1978 Jul; 108(27):1035-40. PubMed ID: 663598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
    Prendergast BD
    Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and biotransformation of chlorpropamide in man.
    Taylor JA
    Clin Pharmacol Ther; 1972; 13(5):710-8. PubMed ID: 5053812
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dialysability of sulfonylurea compounds].
    Herrmann M; Kuhlmann H
    Med Welt; 1978 Sep; 29(37):1453-4. PubMed ID: 692336
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical trial with glypentide. Comparison with the hypoglycemic activity of other sulfonylurea compounds].
    López JM; Khoury G; Fernández RC; COBOS JM; Huelva JL
    Rev Iber Endocrinol; 1976; 23(134):181-96. PubMed ID: 778973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
    Tattersall RB
    Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chlorpropamide-metformin in obese diabetics or diabetics with side effects from sulfonylureas. 2-year results].
    Garcia Viveros M; Prado Vega R; Rull JA; Lozano-Castañeda O
    Prensa Med Mex; 1971; 36(7):347-9. PubMed ID: 5096256
    [No Abstract]   [Full Text] [Related]  

  • 17. [Case of hypersensitivity to sulfonylurea compounds].
    Batko B
    Wiad Lek; 1983 May; 36(9):761-3. PubMed ID: 6613126
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacokinetics and metabolite spectrum of glisoxepide in humans].
    Speck U; Mützel W; Kolb KH; Acksteiner B; Schulze PE
    Arzneimittelforschung; 1974 Mar; 24(0):404-9. PubMed ID: 4408089
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of sugar-reducing therapy on renal function in patients with type II diabetes mellitus].
    Mazurov VI; Novik AA; Nagibovich OA; Romashevskiĭ BV; Guliaeva IV; Kurganova TA
    Klin Med (Mosk); 1998; 76(6):38-41. PubMed ID: 9693499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of a new antidiabetic agent in patients with limited kidney function].
    Rentsch G; Forgó I; Dubach UC
    Schweiz Med Wochenschr; 1972 May; 102(18):650-3. PubMed ID: 5033179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.